Skip to main content
Premium Trial:

Request an Annual Quote

Cellectricon, StressMarq Ink Neurodegenerative Disease Research Deal

NEW YORK — Cellectricon said on Tuesday that it has signed an agreement to use StressMarq Biosciences' reagents for its neurodegenerative research.

Mölndal, Sweden-based Cellectricon provides drug discovery services, with a focus on chronic pain and neurodegenerative disease. Among its areas of research is the spread of neurodegenerative disease-associated peptides, such as amyloid-beta peptides, tau, and alpha-synuclein, that characterizes Alzheimer's disease and Parkinson's disease.

Under the terms of the deal, British Columbia-based StressMarq will provide Cellectricon access to certain of its life science reagents including pre-formed fibrils of tau and alpha-synuclein, which can initiate protein aggregation and induce disease pathology in vitro and in vivo. Additional terms were not disclosed.

"A vital factor for enabling in vitro modelling of neuropathological processes is access to well-characterized reagents such as seed competent fibrils and filaments," Sebastian Illes, Cellectricon's director of central nervous system research, said in a statement. "Our collaboration with StressMarq … will enable us to access their high-quality portfolio of reagents for our services."

The Scan

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.

Study Uncovers Genetic Mutation in Childhood Glaucoma

A study in the Journal of Clinical Investigation ties a heterozygous missense variant in thrombospondin 1 to childhood glaucoma.

Gene Co-Expression Database for Humans, Model Organisms Gets Update

GeneFriends has been updated to include gene and transcript co-expression networks based on RNA-seq data from 46,475 human and 34,322 mouse samples, a new paper in Nucleic Acids Research says.

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.